<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752959</url>
  </required_header>
  <id_info>
    <org_study_id>RAcikgozEsmolol</org_study_id>
    <nct_id>NCT01752959</nct_id>
  </id_info>
  <brief_title>A Comparison of Esmolol and Remifentanil to Reduce Blood Loss</brief_title>
  <official_title>A Randomized Comparison of Esmolol and Remifentanil on Intraoperative Bleeding and Surgical Field Conditionsin Nasal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized study we aimed to compare the effects of esmolol and
      remifentanil on intraoperative bleeding surgical field conditions in nasal surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients with ASA I-IIphysical status assigned for septoplasty will be enrolled in this
      prospective randomized trial. A standardized anesthesia induction and intubation with
      propofol and rocuronium will be used. Patients will be randomized in two groups. Group
      Esmolol (Group E n=30) will receive esmolol 500 mic kg-1 loading dose and a 50-500 mic kg-1
      min-1 infusion and Group Remifentanil (Group R n=30) will receive remifentanil 0.1-0.3 mic
      kg-1 min-1 infusion to induce controlled hypotension. A 50-60 mmHg mean arterial pressure and
      a minimum 50 beat min-1 heart rate is targeted. Heart rate, blood pressures, peripheral
      oxygen saturation and bispectral index spectrum (BIS) will be recorded. Anesthesia
      maintenance will be provided with O2/N2O and desflurane-propofol balanced anesthesia and a
      BIS value 40-60 is targeted. The quality of the surgical field will be assessed by the
      surgeon by using a 10 point visual analog scale (B1) and a 6 point scale (B2) during surgery
      with 5 minute intervals. The amount of bleeding will be calculated at the end of surgery from
      the amount of blood and irrigation fluid collected in the suction tube. All complications and
      side effects will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference between group regarding blood loss</measure>
    <time_frame>intraoperative</time_frame>
    <description>controlled hypotension in nasal surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference between groups regarding side effects and treatments</measure>
    <time_frame>intraoperative</time_frame>
    <description>side effects: more than 20% change in blood pressure and heart rate, treatment includes atropin, ephedrin, nitroglyserine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Deviation Septum Nasal</condition>
  <arm_group>
    <arm_group_label>Remifentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>0.1-0.3 micg/kg/min Remifentanil iv infusion</description>
    <arm_group_label>Remifentanyl</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion</description>
    <arm_group_label>esmolol</arm_group_label>
    <other_name>Brevibloc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II,

          -  between age 20-60

        Exclusion Criteria:

          -  patients having bleeding disorders,

          -  arrhythmia,

          -  hypertension,

          -  endocrine, liver or kidney disease and

          -  those who are on antihypertensive,

          -  anticoagulant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruveyda D Acıkgoz, Trainee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Diskapi Yildirim Beyazit Teaching and Research Hospital, Turkey.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruveyda D Acikgoz, Trainee</last_name>
    <phone>0903125962554</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dilek Yazicioglu, Specialist</last_name>
    <phone>0903125962553</phone>
    <email>dilek.yazicioglu@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06610</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murat Alper, Proffesor</last_name>
      <phone>03125962242</phone>
      <email>muratalper@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Degoute CS, Ray MJ, Manchon M, Dubreuil C, Banssillon V. Remifentanil and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty. Can J Anaesth. 2001 Jan;48(1):20-7.</citation>
    <PMID>11212044</PMID>
  </reference>
  <reference>
    <citation>Shen PH, Weitzel EK, Lai JT, Wormald PJ, Ho CS. Intravenous esmolol infusion improves surgical fields during sevoflurane-anesthetized endoscopic sinus surgery: a double-blind, randomized, placebo-controlled trial. Am J Rhinol Allergy. 2011 Nov-Dec;25(6):e208-11. doi: 10.2500/ajra.2011.25.3701.</citation>
    <PMID>22185726</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Teaching and Research Hospital</investigator_affiliation>
    <investigator_full_name>Dondu Ruveyda Acikgoz</investigator_full_name>
    <investigator_title>Medical Doctor Trainee in Anesthesiology and Reanimation</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

